Home Inherited Disease and Carrier Screening Primary Ciliary Dyskinesia Genetic Test: Ciliary Gene Mutations and Results

Primary Ciliary Dyskinesia Genetic Test: Ciliary Gene Mutations and Results

By
Vita Library
-
3
Learn how primary ciliary dyskinesia genetic testing identifies ciliary gene variants, works with nasal nitric oxide and microscopy, and explains family risk.

A primary ciliary dyskinesia genetic test looks for inherited variants that disrupt the structure or movement of motile cilia. These microscopic structures clear mucus from the airways, help establish organ position before birth, and contribute to reproductive function. When cilia do not work normally, people may have unexplained neonatal respiratory distress, a daily wet cough from early childhood, year-round nasal congestion, recurrent ear and sinus disease, bronchiectasis, laterality differences, or infertility.

Genetic testing has become a central part of diagnosis, but no single result identifies every person with primary ciliary dyskinesia (PCD). More than 50 genes are established causes, several inheritance patterns occur, and some people with convincing disease remain genetically unresolved. A complete evaluation may combine a broad gene panel with nasal nitric oxide, high-speed video microscopy, transmission electron microscopy, immunofluorescence, and specialist clinical assessment. The strongest molecular diagnosis usually finds two disease-causing variants in the same recessive PCD gene, one on each gene copy, or one qualifying variant in a dominant or X-linked gene that fits the phenotype.

  • PCD commonly causes a lifelong wet cough, chronic nasal symptoms, and recurrent respiratory infections beginning early in life.
  • About half of affected people have reversed or otherwise altered organ laterality, but normal organ position does not exclude PCD.
  • Most PCD is autosomal recessive; some forms are X-linked or autosomal dominant.
  • A broad panel is usually more useful than testing only one or two ciliary genes.
  • Normal ciliary ultrastructure does not rule out PCD because several genetic types look normal by electron microscopy.
  • Negative or uncertain DNA results should be interpreted with functional testing at an experienced PCD center.

Table of Contents

What PCD genetic testing examines

Motile cilia are complex cellular machines built from hundreds of proteins. Their internal scaffold, dynein motors, radial spokes, nexin links, central apparatus, docking systems, and assembly factors must work together to create coordinated movement. A pathogenic variant in any one of many genes can disrupt this system and cause PCD.

Frequently tested genes include DNAH5, DNAH11, DNAI1, CCDC39, CCDC40, CCDC103, DNAAF1, DNAAF2, DNAAF3, LRRC6, HEATR2, SPAG1, RSPH1, RSPH3, RSPH4A, RSPH9, HYDIN, CCDC164, CCDC65, CCNO, MCIDAS, FOXJ1, OFD1, RPGR, and others. The list continues to grow, so laboratories should update panels regularly and explain which genes and variant types are covered.

Most testing uses next-generation sequencing to analyze many genes at once. A comprehensive assay should evaluate small sequence variants and, when possible, exon-level deletions and duplications. Some laboratories add copy-number analysis automatically, while others require a separate test. Deep intronic variants, structural rearrangements, repeat-rich regions, low-level mosaicism, or newly discovered genes may not be detected by a standard panel.

The molecular question is not merely whether a cilia-related variant exists. Many people carry harmless variation in these large genes. The laboratory must determine whether the variant is pathogenic, whether the inheritance pattern fits, whether the second required variant is present for a recessive gene, and whether the known gene-related phenotype matches the person’s findings.

For this reason, detailed clinical information improves interpretation. Useful information includes neonatal oxygen need, onset and persistence of wet cough, chronic rhinitis, ear disease, bronchiectasis distribution, organ laterality, congenital heart disease, fertility history, nasal nitric oxide results, ciliary microscopy findings, and affected relatives. A multigene panel is often the best first molecular test because the symptoms do not reliably identify one gene.

PCD is distinct from disorders of nonmotile primary cilia, such as many syndromic kidney or retinal ciliopathies. Some genes can blur that boundary or cause syndromic features, so a broader test may be appropriate when respiratory disease occurs with developmental, kidney, eye, neurologic, or skeletal findings.

Clinical clues that support testing

PCD should be considered when characteristic symptoms begin very early and persist. The pattern is more informative than any single respiratory infection.

Four clinical features are especially useful:

  1. Unexplained neonatal respiratory distress in a term infant, often requiring oxygen for more than a day and beginning several hours after birth.
  2. Daily, year-round wet cough starting before 6 months of age.
  3. Daily, year-round nasal congestion starting before 6 months of age.
  4. Organ laterality difference, such as situs inversus totalis or a more complex heterotaxy pattern.

The likelihood of PCD rises when several are present. However, not everyone has all four. People with normal organ arrangement can have PCD, and some genetic types have milder or atypical early symptoms.

Other clues include recurrent otitis media with hearing difficulty, chronic pansinusitis, repeated pneumonia, unexplained bronchiectasis, clubbing, reduced lung function, and chronic productive cough. In adults, infertility can be an important clue. Many males have reduced sperm motility because sperm tails share structural components with motile cilia. Some females have reduced fertility or increased risk of ectopic pregnancy because fallopian-tube cilia help transport the egg.

Laterality differences occur because embryonic nodal cilia help establish the left-right body axis. About half of people with many classic PCD forms have mirror-image organ arrangement. Others have heterotaxy, which can be associated with complex congenital heart disease, spleen abnormalities, or intestinal malrotation. The older term Kartagener syndrome refers to the combination of PCD features, bronchiectasis, chronic sinus disease, and situs inversus; it describes a clinical subset rather than a separate genetic condition.

PCD can resemble cystic fibrosis, primary immunodeficiency, aspiration, asthma, severe reflux, airway malformations, and post-infectious bronchiectasis. Sweat chloride or CFTR testing, immune studies, and aspiration evaluation may be needed. The presence of asthma or allergies does not exclude PCD, but episodic wheeze alone without a lifelong wet cough is less typical.

Testing should be considered even in adults with longstanding “idiopathic” bronchiectasis when childhood history reveals chronic wet cough, recurrent ear disease, neonatal respiratory distress, or infertility. A delayed diagnosis does not mean the condition began in adulthood.

How genetics and ciliary tests work together

PCD diagnosis has historically required several specialized tests because each method has blind spots. Current practice increasingly places comprehensive genetics at the center, while retaining functional and structural testing for unresolved or discordant cases.

Nasal nitric oxide

Nasal nitric oxide is usually very low in PCD. In cooperative patients, typically school-age children and adults, a standardized chemiluminescence measurement can provide strong diagnostic evidence when repeated on separate occasions. A temporary respiratory infection, cystic fibrosis, poor technique, or nonstandard equipment can also lower the result. It is less reliable in young children who cannot perform the required breathing maneuver.

A low nasal nitric oxide result supports PCD but does not identify the gene or inheritance risk. A normal value makes classic PCD less likely but may occur in some genetic subtypes, so it should not automatically stop evaluation when the clinical picture is strong.

Transmission electron microscopy

Transmission electron microscopy examines ciliary cross-sections for missing outer or inner dynein arms, microtubular disorganization, or central-pair defects. A hallmark defect can confirm PCD. Yet cilia may be secondarily damaged by infection, sampling may be inadequate, and several genetic forms—including many involving DNAH11, HYDIN, radial-spoke proteins, and some assembly factors—can have normal or subtle ultrastructure.

High-speed video microscopy

High-speed video microscopy assesses ciliary beat frequency and pattern. Experienced centers may identify immotile, stiff, circular, hyperkinetic, or poorly coordinated movement. Results depend on sample quality, temperature, infection status, culture methods, and expert interpretation. Secondary dyskinesia from airway inflammation can mimic a primary defect.

Immunofluorescence

Immunofluorescence uses antibodies to see whether selected ciliary proteins are present and correctly located. It can support certain diagnoses and help interpret variants, but available antibody panels do not cover every PCD protein.

Genetic testing

A definitive molecular result can establish PCD even when ultrastructure is normal. It can also identify a subtype, guide family testing, and avoid repeated nasal biopsies. For most recessive genes, two pathogenic or likely pathogenic variants in trans are required. One variant alone is usually not enough.

No result should be interpreted outside the clinical context. A child with two pathogenic variants in a recognized PCD gene and classic symptoms may not need every other test. A person with one uncertain variant, low nasal nitric oxide, and characteristic ciliary movement may need deeper molecular analysis. The diagnostic pathway should be individualized at a center familiar with all methods.

Interpreting positive, negative, and uncertain results

The report should list the gene, transcript, exact DNA and protein changes, classification, zygosity, inheritance pattern, and assay limitations. The key question is whether the findings meet the expected molecular pattern for that gene.

Two pathogenic or likely pathogenic variants in a recessive gene

This usually confirms PCD when the variants are on opposite copies of the same gene and the phenotype is compatible. “Likely pathogenic” is a formal category supported by strong evidence. Parental testing can show that one variant was inherited from each parent and establish phase.

Two variants are not automatically diagnostic if they are in cis on the same chromosome copy. In that arrangement, the other copy may be normal, making the person a carrier rather than affected. Reports sometimes infer phase from family testing or sequencing data, but the basis should be stated.

One pathogenic variant in a dominant gene

Certain FOXJ1 and TUBB4B variants can cause autosomal dominant motile ciliopathy phenotypes. A single qualifying variant may therefore be diagnostic. Some affected people have a new variant not found in either parent. Dominant forms can include developmental or neurologic features in addition to respiratory disease, depending on the gene and variant.

One pathogenic variant in an X-linked gene

Variants in genes such as OFD1, RPGR, or DNAAF6 can cause X-linked PCD or overlapping syndromes. Males with one pathogenic X-linked variant are often more clearly affected. Females may be unaffected carriers, have variable respiratory manifestations because of X-chromosome inactivation, or have features specific to the gene.

One pathogenic variant in a recessive gene

One finding usually indicates carrier status and does not confirm PCD. In a person with strong clinical and functional evidence, a second variant may have been missed. Deletion/duplication analysis, reanalysis, genome sequencing, RNA studies, or a test with improved intronic and structural coverage may be appropriate.

Negative result

A negative panel reduces the chance of a known genetic form but does not rule out PCD. The panel may omit a newly established gene, fail to detect a complex change, or lack sensitivity for deep intronic and structural variants. A person can still receive a clinical or functional diagnosis after expert review.

Variant of uncertain significance

A VUS is not proof of PCD. A recessive gene with one pathogenic variant and one VUS remains unresolved unless additional evidence supports the VUS. Evidence may include segregation with disease, absence from population databases, a predicted splice effect confirmed by RNA, characteristic protein loss on immunofluorescence, or a highly specific ciliary defect. A VUS guide explains why medical and reproductive decisions should not rely on uncertainty alone.

Benign or likely benign variant

These findings are not considered causal. Laboratories may not report them. A report that says “carrier” should specify a pathogenic or likely pathogenic variant, not merely a common benign change.

Inheritance and family risk

Most PCD is autosomal recessive. When both parents carry a pathogenic variant in the same PCD gene, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child who inherited neither familial variant. These probabilities reset with each pregnancy.

Parents of an affected child are usually healthy carriers. Some may have mild respiratory symptoms for unrelated reasons, but carrying one variant in a typical recessive PCD gene does not usually cause PCD. Rare exceptions depend on the gene, variant, or a second unrecognized finding.

The recurrence pattern changes for dominant and X-linked disease. A person with an autosomal dominant pathogenic variant may have a 50% chance of passing it to each child. For X-linked disease, an affected male passes his X chromosome to all daughters and no sons. A female with a pathogenic X-linked variant has a 50% chance of passing it in each pregnancy, although expression can differ by sex and X-inactivation.

Family testing should start from the complete laboratory report. Once the causal variants are known, relatives can have targeted testing rather than an entire panel. Siblings of an affected person may need both genetic and clinical evaluation because an apparently healthy child can have early airway disease that has not yet been recognized.

Reproductive options may include natural conception, prenatal diagnosis, or in vitro fertilization with preimplantation genetic testing for a monogenic condition. These approaches usually require clearly classified familial variants and confirmed phase. A VUS should not ordinarily be used as the sole target for embryo or fetal diagnosis. A genetics professional can explain prenatal testing choices, timing, and limitations.

Partner testing is appropriate for an affected person or known carrier who is planning pregnancy. Testing should cover the relevant gene comprehensively rather than only a small list of common variants, because PCD-causing variants are diverse and population-specific. A negative partner result reduces but may not eliminate residual carrier risk.

Family communication can be complicated when laterality, infertility, or chronic lung disease has been treated as unrelated. A clear written explanation of the gene, variants, and inheritance pattern helps relatives seek accurate testing without assuming that every cough or fertility problem indicates PCD.

Gene-specific patterns and prognosis

Genetic subtype can explain why standard tests differ and can provide broad clues about clinical course. It cannot predict an individual’s exact lung-function trajectory.

DNAH5 and DNAI1 often cause outer dynein arm defects visible on electron microscopy. CCDC39 and CCDC40 commonly cause inner dynein arm loss with microtubular disorganization and are associated, on average, with more severe lung disease. DNAH11 can produce abnormal, often hyperkinetic beating while ciliary ultrastructure appears normal. Radial-spoke genes such as RSPH1, RSPH4A, and RSPH9 often preserve normal organ laterality because the embryonic nodal cilia that determine left-right arrangement have a different structure.

Variants in CCNO or MCIDAS can cause reduced generation of multiple motile cilia rather than a classic internal structural defect. These forms may be severe because airway cells have too few functioning cilia. FOXJ1 can affect motile cilia formation and may be associated with hydrocephalus or laterality differences. X-linked RPGR variants can combine PCD features with retinal degeneration, while some OFD1 variants can produce respiratory disease with developmental or other syndromic findings.

The same gene can produce a spectrum. Variant type, residual protein function, modifying genes, infection history, environmental exposure, access to airway-clearance care, and treatment adherence all influence outcomes. Even siblings with identical variants may differ.

Genotype can be particularly useful when a person has normal electron microscopy. A conclusive DNA result prevents “normal ultrastructure” from being mistaken for exclusion. It can also prompt targeted screening for gene-associated features such as retinal disease, hearing concerns, hydrocephalus, congenital heart disease, or developmental differences.

Genotype is not yet a routine guide to gene-specific approved therapy, but it may determine eligibility for research studies or future molecular treatments. Patients should be cautious about commercial claims. Trial enrollment requires a confirmed diagnosis, exact variant documentation, and review by the study team.

A molecular result should therefore be used to refine care, not to lower expectations or predict life span. Regular lung-function trends, respiratory cultures, imaging when indicated, exacerbation history, hearing, growth, and quality of life are more useful for immediate management.

Care after a genetic diagnosis

A genetic diagnosis should lead to consistent respiratory care. The goal is to improve mucus clearance, treat infection promptly, preserve lung function, and address ear, sinus, fertility, and laterality-related needs.

Airway-clearance therapy is a cornerstone. Techniques may include breathing exercises, positive expiratory pressure devices, oscillating devices, manual methods, exercise, or other approaches selected with a respiratory therapist. Treatment should be practical enough to maintain during school, work, travel, and illness.

Respiratory cultures help identify organisms and guide antibiotics during exacerbations. People with PCD may develop chronic infection with organisms that require specialized management. New or increased cough, sputum, breathlessness, fatigue, fever, or reduced lung function should prompt contact with the care team rather than waiting for severe illness.

Routine care may include spirometry, oxygen assessment when needed, hearing evaluation, ear and sinus care, vaccination, nutrition and growth monitoring, and periodic imaging based on symptoms and clinical practice. Smoking and vaping exposure should be avoided. Exercise can support airway clearance and conditioning but does not replace prescribed treatment.

Children with frequent middle-ear disease need coordinated audiology and education support. Hearing loss can affect language development even when the child seems to respond to sound. Ear procedures should be discussed with clinicians experienced in PCD because persistent drainage and benefits vary.

Adults and adolescents may benefit from early fertility counseling. Semen analysis, reproductive endocrinology evaluation, and assisted reproductive technologies can help, depending on the cause. People with heterotaxy or congenital heart disease may need cardiology and other specialty follow-up independent of lung care.

Patients should keep the genetic report and any ciliary-test reports. The exact gene and variants matter for relatives, reproductive testing, and possible future trials. A general germline testing guide can help families organize records and cascade testing.

Urgent assessment is warranted for severe breathing difficulty, blue or gray color, coughing blood in more than a small streak, chest pain, confusion, dehydration, or a rapidly worsening infection. A genetic diagnosis explains susceptibility but does not make acute respiratory symptoms safe to manage without medical review.

Test limitations and next steps

Before ordering a panel, ask which PCD genes are included, how recently the panel was updated, whether deletion/duplication analysis is built in, and whether the laboratory reports coverage gaps. A large gene count is not enough; the genes must have validated disease associations and the assay must detect relevant variant types.

A negative test may reflect one of several situations:

  • The person does not have PCD.
  • The causal gene is not yet known or was not included.
  • A deep intronic, regulatory, structural, or mosaic variant was missed.
  • One variant was detected but the second is technically hidden.
  • The symptoms arise from another inherited bronchiectasis disorder.
  • The clinical sample or phenotype information was insufficient for interpretation.

When suspicion remains high, an experienced center may review nasal nitric oxide quality, repeat ciliary sampling after infection has resolved, perform immunofluorescence, culture airway cells before video microscopy, or pursue exome or genome sequencing. Reanalysis over time can identify newly recognized genes or reclassified variants. Whole-genome sequencing may help with noncoding and structural variants, although it still does not solve every case.

Sample choice can matter after an allogeneic bone marrow or stem-cell transplant because blood DNA may represent the donor. A laboratory may request saliva with caution, buccal cells, or cultured skin fibroblasts. Recent blood transfusion usually has less lasting impact but should still be disclosed.

Clinical laboratories should not classify a result based only on a computer prediction. Strong interpretation uses population frequency, segregation, functional evidence, RNA effects, ciliary protein localization, known disease mechanism, and consistency with the phenotype. Patients should ask whether the laboratory will issue an amended report if the classification changes.

Do not use a direct-to-consumer raw-data file to diagnose PCD. Consumer arrays sample selected positions and cannot exclude the thousands of possible rare variants across more than 50 genes. Any apparent finding requires confirmation with a clinical specimen and an appropriate diagnostic method.

Finally, a molecular diagnosis does not make repeated functional testing necessary unless it will answer a clinical question. Conversely, a genetically unresolved person with convincing PCD should not lose access to appropriate airway care merely because the current panel is negative. The purpose of testing is to improve diagnosis and management, not to create an artificial boundary around a complex disease.

References

Disclaimer

This article provides general education and does not diagnose primary ciliary dyskinesia or replace specialist testing. Genetic findings, nasal nitric oxide, ciliary microscopy, respiratory history, and family results should be interpreted together by an experienced PCD team and genetics professional. Seek urgent care for severe breathing difficulty, significant coughing of blood, blue or gray color, confusion, or rapidly worsening respiratory illness.

RELATED ARTICLESMORE FROM AUTHOR